托法替布治疗难治性皮肤型皮肌炎的潜在作用
本文报道了4例对多种免疫抑制和免疫调节药物无效的难治性皮肌炎患者,接受托法替布治疗后皮肤及皮肤外表现均显著改善。提示JAK/STAT通路抑制可能通过减轻IFN信号通路改善难治性皮肌炎。
要点
- 托法替布可改善难治性皮肌炎的皮肤及炎症性关节表现
- 4例难治性皮肌炎患者对托法替布均应答良好
- JAK/STAT通路抑制可能通过减轻IFN信号通路发挥作用
核心结论
- 托法替布可改善难治性皮肌炎的皮肤和炎症性关节表现。
研究设计与样本
- 病例系列研究,纳入4例对多种免疫抑制和免疫调节药物无效的难治性皮肌炎患者。
主要发现
- 4例患者接受托法替布后皮肤及皮肤外表现均显著改善。
临床怎么用
- 对常规治疗无效的难治性皮肌炎患者,托法替布可作为潜在治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Some patients with cutaneous DM demonstrate incomplete responses to conventional therapy while some, including those with extra-cutaneous manifestations, experience disease recurrences. Janus kinase/signal transducers and activators of transcription pathway inhibition has been reported to mitigate IFN signalling, which is thought to contribute to disease pathogenesis in DM. Four cases of refractory DM responsive to tofacitinib have been reported in the literature. Our case series investigated the use of tofacitinib in refractory cutaneous DM. METHODS: Our case series includes four subjects with refractory DM who received tofaticinib after failure of several immunosuppressive and immunomodulatory agents. RESULTS: All four subjects responded well to tofacitinib with significant improvement in cutaneous and extra-cutaneous manifestations. CONCLUSION: Tofacitinib can improve cutaneous and inflammatory articular manifestations in refractory DM.
引用
- Moghadam-Kia S, Charlton D, Aggarwal R, et al. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019. PMID: 30608616. doi:10.1093/rheumatology/key366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。